Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 2
R&D Momentum
51/100
Pipeline Velocity
15/100
Trial Completion Rate
90/100
Pipeline Concentration
50/100
Pipeline Freshness
58/100
Strategic Signals
Activity
Last 14 days
Addictions Neuroclinical Assessment
(Epi)Genetic Modulators of Fear Extinction in Alcohol Dependence
Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder
Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness
NIAAA Natural History Protocol
Role of Metal Ion Transporter ZIP8 in Alcohol Related Behaviors
Development of Neuroimaging Methods to Assess the Neurobiology of Addiction
Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation
Computer-Assisted Self-Administration of Ethanol (CASE) in Humans
Nicotinic Receptor Genetic Variation and Alcohol Reward
The Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk Behaviors
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)